Nicole Clegg, CEO and President of Planned Parenthood of Northern New England.

Today, the US Supreme Court halted an attempt to restrict access to mifepristone, one of two medications commonly used in medication abortion.

The case, Louisiana v. FDA, challenged the Food and Drug Administration’s 2023 Risk Evaluation and Mitigation Strategy (REMS) that removed the requirement that medication be dispensed in person in a medical facility.  Had the dispensing rule been allowed to stand, it would have eliminated access to medicadtion abortion through telehealth and mail-order pharmacies for patients across the country — even in Maine.  It is one of the several cases that have been filed by anti-abortion advocates since the Dobbs decision in 2022.

Medication abortion through telehealth is trusted, safe and effective.

“While this politically motivated case is over for now, we know that the attacks on this case will continue.  This attack was rooted in politics, not in science or medicine, but we are relieved that people across the country and here in Northern New England, will have access to medication abortion via telehealth,” said Nicole Clegg, President & CEO, Planned Parenthood of Northern New England.
This case never should have gotten this far and it’s unacceptable that patients have been caught in a legal tug-of-war while trying to access health care.  We know that the next attack is just around the corner, but we are not going anywhere.  We will never stop fighting to control our bodies and our lives no matter what,” the Clegg statement concluded.